Neuromodulation of Central Sensory Integration to Improve Postural Control

Prior treatment

• Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder. Cognitive status assessed via the Telephone Interview of Cognitive Status (mTICS). We will exclude those with marked dementia (score\<31)
• Active chemotherapy, radiation (see below)
• Currently taking anti-epileptic medication
• Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder. Cognitive status assessed via the Telephone Interview of Cognitive Status (mTICS). We will exclude those with marked dementia (score\<31)
• Active chemotherapy, radiation (see below)
• The following criteria is only exclusionary if participant will receive tDCS. Contraindications to transcranial direct simulation (tDCS), including reported seizure within the past 2 years, Currently taking anti-epileptic medication, active use of neuro-active drugs, metal objects anywhere in the head or the neck, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp. Any history of brain or spine surgery
• Active chemotherapy after the first line of 6 cycles is completed will be eligible.

Other illness

• Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance
• Any unstable medical condition
• Myocardial infarction within the past six months
• Any history of brain or spine surgery, known hearing, visual, or vestibular impairment
• Known Brain Metastasis
  • Exclusion for older, taxane-treated breast, ovarian, and endometrial cancer survivors (OTTBCS) performing a single visit:
• Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance
• Any unstable medical condition
• Myocardial infarction within the past six months
• Known hearing, visual, or vestibular impairment
• Known Brain Metastasis
  • Additional Criteria for cancer survivors:

Other

• Inability to stand or walk unassisted for 60 seconds
• Chronic vertigo
• Inability to stand or walk unassisted for 60 seconds
• Chronic vertigo

• Women aged 50-85 years
• Breast, ovarian and/or endometrial cancer survivors, stages I-IV
• Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted.
• Ability to walk without an assistive device
• Ability to speak and read English
• Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD)
• No history of a other cancer, with the exception that non-melanoma skin cancers are permitted
• Own a device with capability to sync the Fitbit
• Women aged 50-85 years
• Ability to walk without an assistive device
• Ability to speak and read English
• Without neurological disease
• No history of cancer
• Own a device with capability to sync the Fitbit
  • Inclusion for older, taxane-treated breast, ovarian, and endometrial cancer survivors (OTTBCS) performing a single visit:
• Women aged 50-85 years
• Breast, ovarian and/or endometrial cancer survivors, stages I-IV
• Completion of taxane chemotherapy treatment. Taxane combined with a history of anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy is permitted. Receiving platin based agents is permitted.
• Ability to walk without an assistive device
• Ability to speak and read English
• Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD)
• No history of a other cancer, with the exception that non-melanoma skin cancers are permitted
• Own a device with capability to sync the Fitbit